Emily K. Kleczko
Affiliations: | 2000-2015 | Craniofacial Biology | University of Colorado Anschutz Medical Campus, Denver, Aurora, CO |
Google:
"Emily Kleczko"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Sisler DJ, Hinz TK, Le AT, et al. (2023) Evaluation of KRAS inhibitor responses in novel murine KRAS lung cancer cell line models. Frontiers in Oncology. 13: 1094123 |
| Kleczko EK, Hinz TK, Nguyen TT, et al. (2023) Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity. Npj Precision Oncology. 7: 15 |
| Kleczko EK, Poczobutt JM, Navarro AC, et al. (2023) Upregulation of complement proteins in lung cancer cells mediates tumor progression. Frontiers in Oncology. 12: 1045690 |
| Kleczko EK, Le AT, Hinz TK, et al. (2023) Novel EGFR-mutant mouse models of lung adenocarcinoma reveal adaptive immunity requirement for durable osimertinib response. Cancer Letters. 216062 |
| Gadwa J, Bickett TE, Darragh LB, et al. (2021) Complement C3a and C5a receptor blockade modulates regulatory T cell conversion in head and neck cancer. Journal For Immunotherapy of Cancer. 9 |
| Johnson AM, Kleczko EK, Nemenoff RA. (2020) Eicosanoids in Cancer: New Roles in Immunoregulation. Frontiers in Pharmacology. 11: 595498 |
| Neuwelt AJ, Kimball AK, Johnson AM, et al. (2020) Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms. Journal For Immunotherapy of Cancer. 8 |
| Hinz TK, Kleczko EK, Singleton KR, et al. (2019) Functional RNAi Screens Define Distinct Protein Kinase Vulnerabilities in EGFR-Dependent HNSCC Cell Lines. Molecular Pharmacology |
| Kleczko EK, Kwak JW, Schenk EL, et al. (2019) Targeting the Complement Pathway as a Therapeutic Strategy in Lung Cancer. Frontiers in Immunology. 10: 954 |
| Bullock BL, Kimball AK, Poczobutt JM, et al. (2019) Tumor-intrinsic response to IFNγ shapes the tumor microenvironment and anti-PD-1 response in NSCLC. Life Science Alliance. 2 |